(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 July 2010 (15.07.2010)

PCT

(10) International Publication Number
WO 2010/080409 A1

(51) International Patent Classification:
*C07D 205/04* (2006.01) *A61P 35/00* (2006.01)
*A61K 31/397* (2006.01) *A61P 37/00* (2006.01)

(21) International Application Number:
PCT/US2009/068143

(22) International Filing Date:
16 December 2009 (16.12.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/203,053 18 December 2008 (18.12.2008) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CISZEWSKI, Lech** [PL/US]; Novartis, One Health Plaza, East Hanover, New Jersey 07936 (US). **DE LA CRUZ, Marilyn** [US/US]; Novartis, One Health Plaza, East Hanover, New Jersey 07936 (US). **KARPINSKI, Piotr H.** [US/US]; Novartis, One Health Plaza, East Hanover, New Jersey 07936 (US). **MUTZ, Michael** [DE/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **RIEGERT, Christian** [FR/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **VOGEL, Caspar** [CH/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **SCHNEEBERGER, Ricardo** [CH/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH).

(74) Agent: **CHAPMAN, Jennifer C.**; Novartis, Patent Department, One Health Plaza, East Hanover, New Jersey 07936 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published**:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2010/080409 A1

(54) **Title**: HEMIFUMARATE SALT OF 1- [4- [1- ( 4 -CYCLOHEXYL-3 -TRIFLUOROMETHYL-BENZYLOXYIMINO ) -ETHYL] -2 -ETHYL-BENZYL] -A ZETIDINE-3-CARBOXYLIC ACID

(57) **Abstract**: This invention relates to a hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of Compound I, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.